A pilot study of topiramate in children with Lennox-Gastaut syndrome

• Autor(a) principal: GUERREIRO,MARILISA M.
• Data de Publicação: 1999
• Outros Autores: MANREZA,MARIA LUIZA G., SCOTONI,ANNA ELISA, SILVA,E.A., GUERREIRO,CARLOS A. M., SOUZA,E.A.P., FERREIRA,V.B., REED,UMBERTINA C., DIAMENT,ARON, TREFIGLIO,R., CHIU,H.C., BACALTCHUK,J.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Arquivos de neuro-psiquiatria (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X1999000200001
• topic: Lennox-Gastaut syndrome; topiramate; epilepsy treatment

We conducted an open, add-on study with topiramate (TPM) as adjunctive therapy in Lennox-Gastaut syndrome (LGS), to assess the long-term efficacy and safety and to evaluate quality of life (QL) measurements in the chronic use of TPM. We studied 19 patients (11 male; age ranging from 4 to 14 years) with uncontrolled seizures receiving 2-3 anti-epileptic drugs. Patients were followed up to 36 months of treatment. A questionnaire was used to query parents about QL. Seven patients completed the study at 36 months and seizure frequency was reduced > 75% in 4, and < 50% in 3 patients. Two children became seizure free for more than 24 months. Most side effects were CNS related, with the most frequent being somnolence and anorexia. These were generally transient. One patient dropped-out due to powder in the urine. None of the patients required hospitalization. At 36 months, patients' alertness (2/7), interaction with environment (5/7), ability to perform daily activities (5/7), and verbal performance (6/7) improved on TPM. We conclude that TPM may be useful as adjunctive therapy in the treatment of LGS. The efficacy of TPM was maintained in long-term treatment in more than 40% of patients, long term safety was confirmed and QL improved on TPM.